DNLI NASDAQ
Denali Therapeutics Inc.
1W: +1.5%
1M: -8.4%
3M: -19.4%
YTD: +18.1%
1Y: +20.4%
3Y: +4.9%
5Y: -56.6%
$19.22
+0.56 (+3.00%)
Weekly Expected Move ±5.8%
$16
$17
$18
$19
$21
Credit Risk of going bust: lower than 80% of companies Debt: 0.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.9%), Denali Therapeutics Inc. would be worth roughly what it owes.
Total debt $27.5M against a stock market value of $3.07B.
Distance to default 9.60 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $13.8M (short-term plus half of long-term), stock volatility 55.5%; Altman Z'' -3.05. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.9%), Denali Therapeutics Inc. would be worth roughly what it owes.
Total debt $27.5M against a stock market value of $3.07B.
Distance to default 9.60 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $13.8M (short-term plus half of long-term), stock volatility 55.5%; Altman Z'' -3.05. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
2 relationships2
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2025-06-03
Earliest Filing
2025-06-03
Latest Filing
investor: 2
Counterparties (Filed by DNLI)
2 relationshipsCompanies named in DNLI's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Baker Brothers Life Sciences, L.P. | — | investor | Entered into a registration rights agreement with Denali Therapeutics Inc. | 2025-06-03 | View |
| 667, L.P. | — | investor | Entered into a registration rights agreement with Denali Therapeutics Inc. | 2025-06-03 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-28 | Acquisition/Disposition; Exhibits | Acquisition | View |
| 2026-06-18 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-06-04 | Shareholder Vote; Exhibits | View | |
| 2026-05-22 | Regulation FD | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-03 | Termination of Agreement; Exhibits | View | |
| 2026-03-31 | Financial Obligation; Regulation FD | View | |
| 2026-03-25 | Regulation FD; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-06 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-10 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-12-04 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-12-04 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-14 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-07 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-06-03 | Entry into Material Definitive Agreement; Submission of Matters to a Vote of Security Holders; Finan | Agreement | View |
| 2025-05-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR